SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Effective patent life in pharmaceuticals
6 references·5 citing·38 second hop
Effective patent life in pharmaceuticals (2000)Effective patent life in pharmaceuticalsPharmacy benefit management, cost-effectiveness analysis and drug formulary decisions (1997)Pharmacy benefit management, …Longer Patents for Increased Generic Competition in the US (1996)Longer Patents for Increased …Returns to R&D on new drug introductions in the 1980s (1994)Returns to R&D on new drug in…Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Optimal Patent Length and Breadth (1990)Optimal Patent Length and Bre…Patents and Innovation: An Empirical Study (1986)Patents and Innovation: An Em…A multi-objective production planning problem with the consideration of time and cost in clinical trials (2019)A multi-objective production …Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation (2010)Using Market-Exclusivity Ince…Intellectual Property Portfolio Securitization: An Evidence Based Analysis (2008)Intellectual Property Portfol…Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exc…Do Patents Perform Like Property? (2008)Do Patents Perform Like Prope…Economic Welfare and the Allocation of Resources for Invention (1962)Patent Statistics as Economic Indicators: A Survey (1990)What Do We Know about Capital Structure? Some Evidence from International Data (1995)Promoting Intellectual Property Monetization in Developing Countries: A Review of Issues and Strategies to Support Knowledge-Driven Growth (2012)Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting, 1965–1988 (1998)The growth of patenting and licensing by U.S. universities: an assessment of the effects of the Bayh–Dole act of 1980 (2001)Industrial Market Structure and Economic Performance. (1971)Product differentiation advantages of pioneering brands (1980)Generic Entry and the Pricing of Pharmaceuticals (1997)Uncertainty and Learning in Pharmaceutical Demand (2005)Killer Acquisitions (2020)Cost of innovation in the pharmaceutical industry (1991)Cutting the cost of drug development? (2004)Generic competition and market exclusivity periods in pharmaceuticals (2007)The Pharmaceutical Industry (2013)On the Misuse of Accounting Rates of Return to Infer Monopoly Profits (2016)Imitation Costs and Patents: An Empirical Study (1981)On the sources and significance of interindustry differences in technological opportunities (1995)What percentage of innovations are patented? empirical estimates for European firms (1998)Measuring innovative performance: is there an advantage in using multiple indicators? (2003)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)The price of innovation: new estimates of drug development costs (2003)The biotechnology sector and US gene patents: Legal challenges to intellectual property rights and the impact on basic research and development (2012)Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)The Managed Health Care Handbook (1998)Pharmacy Benefit Management Companies: Dimensions of Performance (1999)Economic Evaluations of Healthcare Programmes and Decision Making (2005)Providing Prescription Drug Coverage to the Elderly: America's Experiment with Medicare Part D (2008)Supply chain design and analysis: (1998)Introduction to Stochastic Programming (2011)Optimising the assignment of swabs and reagent for PCR testing during a viral epidemic (2020)Price Competition in Pharmaceuticals: The Case of Anti‐infectives (2004)Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)On the Division of Profit in Sequential Innovation (1995)How Do Patent Laws Influence Innovation? Evidence from Nineteenth-Century World's Fairs (2005)Against Intellectual Monopoly (2008)
this work references cited by second hop

References

  • 1986Patents and Innovation: An Empirical Study1,128 cited
  • 1990Optimal Patent Length and Breadth847 cited
  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
  • 1994Returns to R&D on new drug introductions in the 1980s197 cited
  • 1996Longer Patents for Increased Generic Competition in the US136 cited
  • 1997Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions94 cited

Cited by

  • 2008Follow-on biologics: data exclusivity and the balance between innovation and competition89 cited
  • 2010Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation70 cited
  • 2019A multi-objective production planning problem with the consideration of time and cost in clinical trials21 cited
  • 2008Intellectual Property Portfolio Securitization: An Evidence Based Analysis10 cited
  • 2008Do Patents Perform Like Property?10 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work